Dynavax doses first subject in Phase I/II shingles vaccine trial [Yahoo! Finance]
Dynavax Technologies Corporation (DVAX)
Last dynavax technologies corporation earnings: 3/11 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.dynavax.com
Company Research
Source: Yahoo! Finance
The active-controlled, randomised, dose escalation, multi-centre trial is anticipated to enrol around 440 healthy adults aged 50 to 69 years across multiple sites in Australia. It will assess the safety, tolerability, and immunogenicity of Z-1018 compared to the existing shingles vaccine, Shingrix. One of the main goals is to determine the optimal dose of the glycoprotein E (gE) protein and the most effective dosing schedule for future clinical development. Additionally, the study will help in validating a patient-reported outcome measurement tool. This is intended to differentiate Z-1018 based on tolerability and to support potential claims on the vaccine's label. Dynavax expects to release the immunogenicity and safety data in the second half of next year, which will include a comparative analysis of CD4+ T-cells after the second vaccine dose. Dynavax chief medical officer Rob Janssen said: “We believe there is an opportunity to develop an improved shingles vaccine with
Show less
Read more
Impact Snapshot
Event Time:
DVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DVAX alerts
High impacting Dynavax Technologies Corporation news events
Weekly update
A roundup of the hottest topics
DVAX
News
- Dynavax Technologies Co. (NASDAQ: DVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.MarketBeat
- Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program [Yahoo! Finance]Yahoo! Finance
- Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine ProgramPR Newswire
- TwoStep Therapeutics Launches with Funding to Advance Broadly Applicable Targeting Platform for Solid Tumors [Yahoo! Finance]Yahoo! Finance
- Dynavax to Present at Upcoming Investor ConferencesPR Newswire
DVAX
Earnings
- 5/8/24 - Miss
DVAX
Sec Filings
- 6/3/24 - Form 4
- 5/28/24 - Form 4
- 5/28/24 - Form 4
- DVAX's page on the SEC website